
Ten Factors Impacting the Likelihood a Patient Recovers After Addiction Treatment

Vista's outcomes research has identified ten factors that have a substantial impact on whether patients are able to abstain from alcohol and all non-prescribed drugs for at least the last 30 days at one year post-treatment. Most of these factors are under the control of the treatment provider and/or the patient.

1. The Effectiveness of the Treatment Provider:

Variation in One Year Post-Treatment Abstinence Rates by Rehab

(among rehabs with at least 50 adult, non-professional patients who were discharged between 7/1/16 & 12/31/21)




Source: Vista Research Group, Inc.

2. Whether the Patient Successfully Completes All Recommended Treatment:

Impact of Completing Treatment on Twelve-Month Post-Treatment Abstinence Rate

(among adult, non-professional SUD patients discharged between 7/1/16 and 12/31/21)



In Jail, 0% Died, 1%

Abstinent Since
Treatment, 14%

Abstinent Last
30 Days, 12%


Couldn't Be
Reached,
67%


Used Last 30
Days, 6%

Unknown Usage
Last 30 Days, 0%

Abstinent At Least Last 30 Days: 26%

3. The Length of Time The Patient Remains in Treatment:






4. The Patient's Motivation to Recover:

Vista Research


12 Month Post-Treatment Abstinence Rates by Motivation to Remain Sober at Intake



5. The Severity of the Patient's PTSD Symptoms at Discharge:

Vista Research






6. The Actions Patients Take After Treatment to Remain Abstinent:

Vista Research

Actions Taken For At Least Six Months Post-Treatment That Appear to Have Helped Patients Remain Abstinent at Twelve Months

(among adult, non-professional SUD patients discharged between 7/1/2016 and 12/31/2021)

- Abstinent for at least L30D at 12M post-treatment (n=4,726)
- Used drugs/alcohol in L30D at 12M post-treatment (n=856)




Other factors that impact the likelihood a patient will recover after treatment are set prior to the patient entering treatment:

7. The Health Insurance Company Paying for the Treatment:

Variation in One Year Post-Treatment Abstinence Rates by Payer

(among health insurance companies with at least 25 adult, non-professional members who were discharged between 7/1/16 & 12/31/21)



Source: Vista Research Group

8. The Patient's Primary Drug of Choice:


Vista Research

Abstinence Rates by Primary Drug of Choice at Twelve Months Post-Treatment % of Patients Who Were Reachable & Claimed To Have Been Abstinent For At Least the Last 30 Days at 12 Months (among adult, non-professional SUD patients discharged between 7/1/16 and 12/31/21) 50% 40% 40% 36% 34% 33% 32% 31% 30% 30% 14% 27% 13% 12% 11% 10% 13% 12% 11% 20% 22% 22% 10% 19% 17% 16% 0% Alcohol Meth. Marij. Benzos. Pres. Opioids Amph. Heroin/Fentanyl Cocaine (n=6,744)(n=772)(n=906)(n=516)(n=1,416)(n=215)(n=684)(n=1,397)■ Abstinent Since Treatment Abstinent Last 30 Days

9. The Number of Times The Patient Has Previously Attended SUD Treatment:

Vista Research

Twelve Month Post-Treatment Abstinent Rates By Number of Previous SUD Treatment Episodes



■ Abstinent Since Treatment Abstinent Last 30 Days

(n=766)

(n=779)

(n=654)

(n=515)

(n=1,273)

10. Whether The Patient Smokes or Uses Tobacco:

(n=3,572)

(n=5,664)

Vista Research

Abstinence Rates at Twelve Months Post-Treatment Compared to Tobacco Usage at Intake

